“Ozempic causes depression and suicidal thoughts.”
What the evidence shows
After early post-marketing reports, the FDA and Europe's regulators investigated whether GLP-1 drugs raise the risk of suicidal thoughts or behavior. The FDA's January 2024 communication was preliminary and found no clear signal but noted the event numbers were small. Its conclusive review — a meta-analysis of 91 placebo-controlled trials with 107,910 participants — found no increased risk of suicidal ideation or behavior, or of related events like depression, anxiety, or irritability. On that basis, in January 2026 the FDA requested removal of the suicidal-ideation-and-behavior warning from GLP-1 labels. The EMA's PRAC reached a similar no-causal-link conclusion in April 2024, and some large cohort studies even report lower rates of suicidal ideation in treated patients.
What we still don’t know
"No signal in the pooled trials" is strong but not the same as "impossible in any individual." Trials can under-capture psychiatric events, and people with active severe mental illness were often excluded, so rare or subgroup effects can't be fully ruled out, and pharmacovigilance continues. Mood changes can also accompany major life shifts around rapid weight loss, which is a different question from a direct drug effect.
Why the claim misleads
The claim states as fact something the best available evidence specifically failed to find — and that a major regulator judged strong enough to remove from the label. It's a textbook case of anecdotes and a precautionary early warning being read as proven cause. Anyone experiencing new depression or thoughts of self-harm should of course contact a clinician promptly; that's true regardless of what medication they take.
Graded by The Peptide Era · evidence, not hype